X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES NATCO PHARMA SUVEN LIFESCIENCES/
NATCO PHARMA
 
P/E (TTM) x 19.1 13.4 142.7% View Chart
P/BV x 3.7 2.8 133.6% View Chart
Dividend Yield % 0.6 1.6 38.4%  

Financials

 SUVEN LIFESCIENCES   NATCO PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
NATCO PHARMA
Mar-18
SUVEN LIFESCIENCES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs2511,080 23.2%   
Low Rs155671 23.1%   
Sales per share (Unadj.) Rs49.1592.1 8.3%  
Earnings per share (Unadj.) Rs9.7188.4 5.2%  
Cash flow per share (Unadj.) Rs11.4206.3 5.5%  
Dividends per share (Unadj.) Rs1.508.25 18.2%  
Dividend yield (eoy) %0.70.9 78.5%  
Book value per share (Unadj.) Rs60.3833.6 7.2%  
Shares outstanding (eoy) m127.2836.90 344.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.11.5 279.3%   
Avg P/E ratio x20.94.6 449.2%  
P/CF ratio (eoy) x17.84.2 419.7%  
Price / Book Value ratio x3.41.1 320.4%  
Dividend payout %15.44.4 352.5%   
Avg Mkt Cap Rs m25,82532,311 79.9%   
No. of employees `0001.14.8 22.2%   
Total wages/salary Rs m6133,256 18.8%   
Avg. sales/employee Rs Th5,832.64,522.5 129.0%   
Avg. wages/employee Rs Th571.5674.0 84.8%   
Avg. net profit/employee Rs Th1,153.81,439.0 80.2%   
INCOME DATA
Net Sales Rs m6,25321,848 28.6%  
Other income Rs m233404 57.6%   
Total revenues Rs m6,48522,252 29.1%   
Gross profit Rs m1,9829,284 21.3%  
Depreciation Rs m213662 32.2%   
Interest Rs m46154 30.1%   
Profit before tax Rs m1,9558,872 22.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,920 37.4%   
Profit after tax Rs m1,2376,952 17.8%  
Gross profit margin %31.742.5 74.6%  
Effective tax rate %36.721.6 169.8%   
Net profit margin %19.831.8 62.2%  
BALANCE SHEET DATA
Current assets Rs m5,62221,307 26.4%   
Current liabilities Rs m1,1685,920 19.7%   
Net working cap to sales %71.270.4 101.2%  
Current ratio x4.83.6 133.8%  
Inventory Days Days8173 111.2%  
Debtors Days Days36107 33.7%  
Net fixed assets Rs m3,32514,986 22.2%   
Share capital Rs m127369 34.5%   
"Free" reserves Rs m7,54730,353 24.9%   
Net worth Rs m7,67430,760 24.9%   
Long term debt Rs m140-   
Total assets Rs m9,13537,151 24.6%  
Interest coverage x43.258.6 73.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 116.4%   
Return on assets %14.019.1 73.4%  
Return on equity %16.122.6 71.3%  
Return on capital %26.029.3 88.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06610,322 49.1%   
Fx outflow Rs m2,0012,978 67.2%   
Net fx Rs m3,0657,343 41.7%   
CASH FLOW
From Operations Rs m6994,636 15.1%  
From Investments Rs m-6-11,155 0.1%  
From Financial Activity Rs m-5776,509 -8.9%  
Net Cashflow Rs m116-18 -646.1%  

Share Holding

Indian Promoters % 63.4 52.0 121.8%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.0 7.8 -  
FIIs % 0.0 16.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 26.0 140.4%  
Shareholders   37,287 25,395 146.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 17, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS